Ascend Clinical becomes first user of new artificial intelligence renal care solution
Click Here to Manage Email Alerts
SambaNova Systems and DeLorean Artificial Intelligence announced a new subscription artificial intelligence solution that Ascend Clinical has chosen to leverage with learning models, according to a press release.
“We are committed to providing world-class care to our patients, so our laboratories need the most innovative technology," Paul F. Beyer, CEO of Ascend, said in the release. “We’re looking forward to advancing our AI initiatives to provide a higher level of precision and improve our customers’ insights into their own data.”
Ascend intends to use the artificial intelligence (AI) solution to classify, track and transition kidney patients through disease stages. Additionally, the solution is designed to enable providers with the “next best actions” for patient care and recommendations specific to a patient’s flow rate for infusion and other medical needs.
According to the release, the AI solution may reduce operating costs and increase revenue.
“The solution will provide Ascend customers with value-based care by providing them with precise classifications — faster — and timely treatment recommendations along their patient journey,” Severence MacLaughlin, PhD, CEO and founder of DeLorean Artificial Intelligence, said in the release.
Click Here to Manage Email Alerts